OCA
ARQT icon

Octagon Capital Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Octagon Capital Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$2.81M – 30
2020
Q4 		$2.81M Buy
+100,000
New +$2.45M 0.98% 27

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Octagon Capital Advisors's ARQT Position: Q1 2021 in Review

Octagon Capital Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q1 2021, closing a stake of 100,000 shares — an estimated $2.81M sold.

Octagon Capital Advisors first reported a position in ARQT in Q4 2020 and held it in 1 quarter. The position peaked at $2.81M in Q4 2020. 94 funds tracked by Wall St. Rank hold ARQT as of Q1 2021.

  • Octagon Capital Advisors reported no remaining Arcutis Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 100,000 Arcutis Biotherapeutics shares in Q1 2021, an estimated $2.81M.
  • Octagon Capital Advisors first reported a position in Arcutis Biotherapeutics in Q4 2020 and held it in 1 quarter.
  • Octagon Capital Advisors's Arcutis Biotherapeutics position peaked at $2.81M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2021.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.